Translational predictions for brain therapeutics
Most CNS programs chase the wrong indication, patients or endpoints.
Theremia predicts where your molecule is most likely to work. We rank the diseases and phenotypes it could address, explain the biology behind each call, and hand you blood-accessible biomarkers to track it. You commit preclinical budget on evidence, not a hunch.
What changes with Theremia
Shorter programs, lower spend, better odds in Phase 2.
preclinical R&D reduction
R&D cost savings
Phase 2 success rate
What you'll get
The insights in your report
Asset CNS-X, a brain-penetrant modulator of an upstream neuro-inflammatory pathway. Open any deliverable to see the shape of the insight. Synthetic data; the format is real.
Where your molecule is most likely to work
Asset CNS-X ranks #4 of ~26,000, ahead of two of your current targets.
- #4 · Indication A (movement disorder) · Shared upstream inflammatory cascadeStrong · New
- #11 · Indication B (your target) · Confirms your primary indicationStrong
- #38 · Indication C (neurodegenerative) · Shared downstream effectorSolid
- #52 · Indication D (your target) · Below high-conviction thresholdEmerging
Illustrative samples with synthetic data, shaped like real Theremia deliverables. Not actual predictions.
Proof it works · Validation
We ran this blinded on a known answer: esketamine.
Same ranked output as the sample above, but on a drug whose answer is already documented, so you can check it. We stripped all clinical knowledge from the graph, kept only molecular pharmacology, and the model rebuilt esketamine's real indications and side effects.
100%
documented indications in the top 13 of ~26,000
#1
treatment-resistant depression, at phenotype level
18 / 20
predicted side effects clinically supported
0.85
AUPRC, top of every CNS baseline
Request a pilot analysis
See where your asset is predicted to work
Tell us about your molecule and what a useful result would look like. We reply within two business days, and everything is treated as confidential.